ATE414697T1 - Nf-kb-inhibitoren - Google Patents

Nf-kb-inhibitoren

Info

Publication number
ATE414697T1
ATE414697T1 AT02800491T AT02800491T ATE414697T1 AT E414697 T1 ATE414697 T1 AT E414697T1 AT 02800491 T AT02800491 T AT 02800491T AT 02800491 T AT02800491 T AT 02800491T AT E414697 T1 ATE414697 T1 AT E414697T1
Authority
AT
Austria
Prior art keywords
kappab
inhibitors
diseases
activation
aminothiophene
Prior art date
Application number
AT02800491T
Other languages
English (en)
Inventor
Zehong Wan
Joelle BURGESS
James Callahan
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE414697T1 publication Critical patent/ATE414697T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
AT02800491T 2001-10-04 2002-10-04 Nf-kb-inhibitoren ATE414697T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32697601P 2001-10-04 2001-10-04

Publications (1)

Publication Number Publication Date
ATE414697T1 true ATE414697T1 (de) 2008-12-15

Family

ID=23274589

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02800491T ATE414697T1 (de) 2001-10-04 2002-10-04 Nf-kb-inhibitoren

Country Status (7)

Country Link
US (1) US7166639B2 (de)
EP (1) EP1448545B1 (de)
JP (1) JP2005506334A (de)
AT (1) ATE414697T1 (de)
DE (1) DE60229975D1 (de)
ES (1) ES2315430T3 (de)
WO (1) WO2003029242A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
BR0210357A (pt) * 2001-06-11 2004-06-29 Shire Biochem Inc Composto e métodos para o tratamento ou a prevenção de infecções pelo flavivìrus
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
AR039280A1 (es) 2002-04-11 2005-02-16 Smithkline Beecham Corp Compuesto de aminotiofeno y su uso para preparar una composicion farmaceutica
EP1532133A4 (de) * 2002-06-06 2006-11-15 Smithkline Beecham Corp Nf-:b-inhibitoren
SE0202280D0 (sv) * 2002-07-19 2002-07-19 Astrazeneca Ab Novel compounds
SE0202279D0 (sv) * 2002-07-19 2002-07-19 Astrazeneca Ab Novel comppounds
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
EP1569924A4 (de) * 2002-12-06 2007-02-21 Smithkline Beecham Corp Nf-kb-inhibitoren
DE60332482D1 (de) * 2002-12-10 2010-06-17 Virochem Pharma Inc Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
CA2535652A1 (en) 2003-08-15 2005-02-24 Astrazeneca Ab Substituted thiophenes and uses thereof
WO2005056562A1 (en) * 2003-12-05 2005-06-23 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxylic acid amide compounds as ikk inhibitors
DE602004031777D1 (en) * 2004-01-05 2011-04-21 Astrazeneca Ab Thiophenderivate als chk-1-inhibitoren
GB0402809D0 (en) * 2004-02-09 2004-03-10 Glaxo Group Ltd Chemical compounds
CN1968954A (zh) * 2004-04-12 2007-05-23 三共株式会社 噻吩并吡啶衍生物
KR20090031459A (ko) 2005-03-29 2009-03-25 이코스 코포레이션 Ｃｈｋ1 억제에 유용한 헤테로아릴 우레아 유도체
MX2007014117A (es) * 2005-05-13 2008-02-05 Virochem Pharma Inc Compuestos y metodos para el tratamiento o prevencion de infecciones de flavivirus.
JP2009526855A (ja) 2006-02-16 2009-07-23 ミレニアム・ファーマシューティカルズ・インコーポレイテッド アルファカルボリンおよびその使用
AP2579A (en) 2006-11-15 2013-01-29 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of flavivirus infections
MX2010011545A (es) 2008-04-21 2011-04-11 Otonomy Inc Formulaciones para tratar enfermedades y afecciones del oido.
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
JP2010006717A (ja) * 2008-06-24 2010-01-14 Kyorin Pharmaceut Co Ltd ジヒドロチエノ［２，３−ｅ］インダゾール化合物
KR101323448B1 (ko) 2008-10-02 2013-11-27 아사히 가세이 파마 가부시키가이샤 ８위 치환 이소퀴놀린 유도체 및 이의 용도
US20100137843A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100135984A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
WO2011077502A1 (ja) * 2009-12-21 2011-06-30 杏林製薬株式会社 ジヒドロチエノ［２，３－ｅ］インダゾール化合物
EP2520292A1 (de) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Verwendung von Spirangienen zur Behandlung oder Prävention von IL-8- oder IL-6-vermittelten Erkrankungen
EP2898102A4 (de) 2012-09-20 2016-05-18 Univ Emory Klassifizierer der nf-kb-pfadaktivierung sowie vorrichtungen und verfahren zur verwendung davon
CN109689027A (zh) 2016-06-29 2019-04-26 奥德纳米有限公司 甘油三酯耳用制剂及其用途
EP3652542A1 (de) 2017-07-14 2020-05-20 Protea Biopharma N.V. Verfahren und vorrichtungen zur diagnose und / oder behandlung einer ermüdungserkrankung
ES3011633T3 (en) * 2017-08-31 2025-04-07 Ahammune Biosciences Private Ltd Thiophene compounds, process for synthesis and use thereof for the treatment of autoimmune disorders
CN115161289B (zh) * 2022-03-14 2023-12-05 东南大学 一种用于炎症性疾病治疗的重组腺相关病毒及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468012A (en) * 1973-08-09 1977-03-23 Beecham Group Ltd 2-amino-3-carboxy-thiophene derivatives
DE4039734A1 (de) 1990-12-13 1992-06-17 Basf Ag Substituierte 2-aminothiophene enthaltende herbizide mittel
US6274590B1 (en) * 1993-01-15 2001-08-14 G. D. Searle & Co. Method of treating skin related conditions
DE19642451A1 (de) 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophencarbonsäureamide
HU228111B1 (en) * 1998-07-08 2012-11-28 Sanofi Aventis Deutschland Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
JP2004523476A (ja) 2000-10-12 2004-08-05 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
US6713638B2 (en) * 2001-05-18 2004-03-30 Joel M. Linden 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
BR0210357A (pt) * 2001-06-11 2004-06-29 Shire Biochem Inc Composto e métodos para o tratamento ou a prevenção de infecções pelo flavivìrus
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US6835745B2 (en) * 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
US7084178B2 (en) * 2003-11-26 2006-08-01 Bristol-Myers Squibb Company Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives

Also Published As

Publication number Publication date
WO2003029242A1 (en) 2003-04-10
EP1448545A4 (de) 2005-01-12
ES2315430T3 (es) 2009-04-01
US20040192943A1 (en) 2004-09-30
DE60229975D1 (de) 2009-01-02
JP2005506334A (ja) 2005-03-03
US7166639B2 (en) 2007-01-23
EP1448545A1 (de) 2004-08-25
EP1448545B1 (de) 2008-11-19

Similar Documents

Publication Publication Date Title
ATE414697T1 (de) Nf-kb-inhibitoren
PL1660507T5 (pl) Inhibitory proteazomu oraz sposoby ich stosowania
EA200300906A1 (ru) Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7
SE0203752D0 (sv) New compounds
DE60319364D1 (de) Substituierte pyrroline als kinase inhibitoren
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
IL229124A0 (en) Inhibitors with a mutant form of kit
ATE513550T1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
IS8913A (is) Afleiður 4-tetrazólýl-4-fenýlpiperidíns til þess að meðhöndla verk
TNSN05044A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
DE60234873D1 (de) Verwendung von COX-2 Inhibitoren zur Behandlung von affectiven Störungen
WO2002030353A3 (en) NF-λB INHIBITORS
ATE382048T1 (de) Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen
ATE358673T1 (de) Nf-kb-inhibitoren
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE60329326D1 (de) Tace inhibitoren
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
ATE353667T1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
WO2003086309A3 (en) NF-κB INHIBITORS
ATE300944T1 (de) Verwendung von substituierten distamycin- acryloylderivaten zur behandlung von tumoren die mit erhöhten glutathion-spiegeln zusammenhängen
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
ATE376416T1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties